What Is Kawasaki Disease?

Kawasaki disease, also referred to as Kawasaki syndrome or mucocutaneous lymph node syndrome, represents one of the most common causes of acquired heart disease in children across developed nations. This acute, self-limited vasculitis predominantly affects children between six months and five years of age, though cases outside this range do occur. The hallmark pathological process involves inflammation targeting medium-sized arteries throughout the body, with the coronary arteries being the most clinically significant site. Without timely intervention, approximately 25% of affected children develop coronary artery aneurysms, which can lead to myocardial infarction, arrhythmias, and long-term cardiac morbidity.

First described by Japanese pediatrician Tomisaku Kawasaki in 1967, the condition was initially thought to be a benign febrile illness. It took several years before the cardiac complications were fully appreciated, prompting a paradigm shift in how clinicians approach persistent fever in young children. Today, Kawasaki disease is recognized globally, with the highest incidence observed in children of East Asian descent, particularly those of Japanese, Korean, and Chinese heritage. The incidence rate in Japan is roughly 300–400 per 100,000 children under five years, compared to 20–25 per 100,000 in the United States and approximately 5–15 per 100,000 in Europe.

The precise etiology remains unknown despite decades of investigation. The leading hypothesis centers on an infectious trigger—possibly a viral pathogen or bacterial superantigen—that elicits an exaggerated inflammatory response in genetically susceptible hosts. The disease demonstrates seasonal variation, with peaks in winter and early spring in temperate climates, further supporting an infectious trigger. Genetic susceptibility studies have identified polymorphisms in genes related to immune regulation, including ITPKC, CASP3, and FCGR2A, which influence both disease susceptibility and response to treatment. Kawasaki disease is not contagious and does not spread from child to child, which reinforces the concept that individual host factors play a critical role in disease expression.

The acute vasculitic process in Kawasaki disease is characterized by infiltration of the arterial wall by neutrophils, followed by lymphocytes and macrophages. This inflammatory cascade leads to endothelial dysfunction, disruption of the internal elastic lamina, and eventually, weakening of the vessel wall. The coronary arteries are particularly vulnerable because of their unique hemodynamic properties and anatomic structure. In severe cases, the vessel wall becomes aneurysmal, creating a nidus for thrombus formation and potential ischemic events.

Epidemiology at a Glance

  • Annual incidence in Japan: approximately 300–400 per 100,000 children under 5 years
  • United States incidence: about 20–25 per 100,000 children under 5 years
  • Peak age: 12–24 months; infants under 6 months are at highest risk for incomplete presentation and coronary complications
  • Male-to-female ratio: 1.5:1, with boys having a slightly higher risk of coronary artery involvement
  • Recurrence rate: approximately 1–3%, more common in younger children at first episode

Recognizing the Symptoms Early

Early recognition of Kawasaki disease remains one of the most challenging aspects of pediatric clinical practice. The initial symptoms overlap substantially with common childhood viral infections, which can lead to diagnostic delays. The hallmark feature is a persistent high fever, typically exceeding 39°C (102°F), that lasts for at least five days. However, many clinicians now initiate treatment before day five if the classic clinical features are present, as earlier intervention is associated with better outcomes. The fever is characteristically unresponsive to standard antipyretics and antibiotics, which can serve as a subtle diagnostic clue.

The classic diagnostic criteria are organized around five principal clinical features, often remembered with the mnemonic "Fever plus four of five." To meet the complete diagnostic criteria, a child must have fever plus at least four of the following five manifestations:

  • Bilateral conjunctival injection – non-exudative, painless redness of the conjunctivae that spares the limbus; typically appears within the first few days of fever
  • Oral mucous membrane changes – erythema and cracking of the lips, strawberry tongue with prominent red papillae, diffuse erythema of the oropharyngeal mucosa without discrete lesions
  • Polymorphous rash – truncal, non-vesicular rash that can be morbilliform, scarlatiniform, target-like, or urticarial; typically spares the extremities
  • Extremity changes – erythema and edema of the hands and feet during the acute phase; periungual desquamation beginning around the nail beds during the subacute phase (typically 2–3 weeks after fever onset)
  • Cervical lymphadenopathy – usually unilateral, greater than 1.5 cm in diameter, may be tender, and is often the least common of the five features

Not all children present with the full constellation of findings. Incomplete Kawasaki disease describes cases where fever is present with fewer than four principal criteria. This variant is particularly common in younger infants (under six months of age) and in older children (over five years). Paradoxically, children with incomplete Kawasaki disease are at disproportionately high risk for coronary artery involvement, likely because the diagnosis is delayed or missed entirely. Clinicians must maintain a high index of suspicion and rely on supplemental laboratory and echocardiographic findings when the clinical presentation is equivocal.

The timing of symptom onset and evolution can provide important diagnostic clues. The acute febrile phase generally lasts 1–2 weeks and is characterized by fever and the acute inflammatory manifestations. The subacute phase extends from approximately weeks 2–4, during which fever resolves but cardiac risk peaks. The convalescent phase begins when clinical signs subside, though laboratory abnormalities may persist for several weeks.

Supporting Laboratory and Echocardiographic Findings

No single laboratory test is diagnostic for Kawasaki disease, but a characteristic pattern of abnormalities is highly supportive. Key findings include:

  • Elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) – often markedly elevated
  • Leukocytosis with neutrophil predominance, often exceeding 15,000/µL
  • Normocytic anemia that may develop during the acute phase
  • Thrombocytosis after the first week, with platelet counts frequently exceeding 500,000/µL and sometimes reaching 1,000,000/µL
  • Hypoalbuminemia, reflecting systemic inflammation and capillary leak
  • Elevated liver transaminases, often mild to moderate
  • Sterile pyuria – white blood cells in the urine without bacteriuria

Echocardiography is the cornerstone of cardiac assessment and should be performed as soon as the diagnosis is suspected. Baseline imaging evaluates coronary artery dimensions, ventricular function, and the presence of pericardial effusion. Coronary artery dimensions are assessed using Z-scores, which standardize measurements for body surface area. A Z-score greater than 2.5 is considered abnormal and indicates coronary artery dilatation or aneurysm. Repeat echocardiography is recommended at 1–2 weeks and again at 4–6 weeks after treatment initiation. In children with persistent coronary abnormalities, long-term surveillance imaging is required.

In recent years, additional imaging modalities have been employed for risk stratification. Cardiac magnetic resonance angiography can provide detailed assessment of coronary artery anatomy and myocardial viability. Computed tomography coronary angiography is sometimes used in older children, though concerns about radiation exposure limit its routine use. Stress testing, including exercise echocardiography or nuclear perfusion imaging, may be indicated in children with established coronary aneurysms to assess for inducible ischemia.

Differential Diagnoses to Consider

The differential diagnosis for Kawasaki disease is broad, particularly in the first few days of illness. Common mimickers include:

  • Viral exanthems – measles, adenovirus, enterovirus, Epstein-Barr virus, and human herpesvirus 6 (roseola)
  • Scarlet fever caused by group A Streptococcus
  • Drug reactions, including Stevens-Johnson syndrome and serum sickness
  • Systemic-onset juvenile idiopathic arthritis (Still disease)
  • Toxic shock syndrome (staphylococcal or streptococcal)
  • Rickettsial infections such as Rocky Mountain spotted fever
  • Leptospirosis and other spirochetal infections

Clinical judgment, serial observation, and selective laboratory testing are essential for distinguishing these conditions. A child with persistent unexplained fever for five or more days who exhibits even two or three of the classic features should undergo echocardiography and inflammatory marker testing without delay. In the current era, clinicians must also consider multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 infection, which shares overlapping features with Kawasaki disease but typically presents in older children with gastrointestinal symptoms and myocardial dysfunction.

Diagnostic Pathways and Scoring Systems

The American Heart Association (AHA) has established diagnostic algorithms to guide clinicians in evaluating suspected Kawasaki disease. For children with fever lasting five or more days accompanied by four or more principal clinical features, the diagnosis can be made on clinical grounds alone. When fewer than four principal features are present, the algorithm incorporates laboratory criteria and echocardiographic findings to determine whether the diagnosis of incomplete Kawasaki disease is appropriate.

Several scoring systems have been developed to predict the risk of coronary artery aneurysms and IVIG resistance. The most widely used is the Kobayashi score, developed in Japan, which assigns points based on age, days of illness at presentation, platelet count, CRP, albumin, sodium, and neutrophil percentage. A score of 4 or higher predicts a high risk of IVIG resistance and coronary abnormalities. Similar systems include the Egami score and the Harada score. While these scoring systems have been validated primarily in Japanese populations, they are increasingly used in other settings to guide adjunctive therapy decisions, particularly regarding the early use of corticosteroids.

In the United States and Europe, the AHA algorithm emphasizes clinical judgment combined with serial assessment. Laboratory markers such as N-terminal pro-B-type natriuretic peptide (NT-proBNP) have emerged as potentially useful adjuncts, particularly in distinguishing Kawasaki disease from febrile viral illnesses. Elevated NT-proBNP levels correlate with myocardial inflammation and may help identify children at higher risk for cardiac involvement.

Treatment Options: From Acute Management to Long-Term Care

The standard treatment for acute Kawasaki disease rests on two pillars: high-dose intravenous immunoglobulin (IVIG) and high-dose aspirin. The goal of acute therapy is to suppress systemic inflammation and prevent coronary artery damage.

Intravenous Immunoglobulin (IVIG)

IVIG is administered as a single dose of 2 g/kg infused over 10–12 hours. The optimal timing is within the first 10 days of illness, with the greatest benefit observed when treatment is initiated within the first 7 days. The mechanism of action of IVIG is not fully understood but likely involves multiple immunomodulatory effects: neutralization of a putative superantigen, down-regulation of pro-inflammatory cytokines, modulation of Fc receptor expression, and expansion of regulatory T-cell populations.

Approximately 10–20% of children do not respond to the initial IVIG dose. Non-response is defined as persistent or recrudescent fever (temperature ≥38.0°C) 36 hours after completion of the IVIG infusion. These children are at significantly higher risk for coronary artery aneurysms. Management options for IVIG-resistant Kawasaki disease include a second dose of IVIG (2 g/kg), high-dose pulse methylprednisolone (30 mg/kg/day for 1–3 days), infliximab (a monoclonal antibody targeting TNF-alpha at 5 mg/kg), or cyclosporine. Evidence from randomized trials, particularly the RAISE study, supports the use of adjunctive corticosteroids in high-risk patients identified by scoring systems, showing a reduced incidence of coronary artery abnormalities.

Aspirin Therapy

During the acute febrile phase, aspirin is used at anti-inflammatory doses of 30–50 mg/kg/day divided into four doses. Once the child has been afebrile for 48–72 hours and acute inflammation has subsided, the dose is reduced to an anti-platelet dose of 3–5 mg/kg/day given once daily. This low-dose aspirin is continued for at least 6–8 weeks after disease onset. In children who develop coronary aneurysms, low-dose aspirin is continued indefinitely.

Concerns about Reye syndrome have prompted caution regarding aspirin use in children, but the risk is extremely low when aspirin is used under medical supervision and the child is vaccinated against influenza and varicella. Annual influenza vaccination is recommended for all children on long-term aspirin therapy.

Importance of Early and Aggressive Treatment

Treatment within the first 10 days of fever reduces the risk of coronary artery aneurysms from approximately 25% to less than 5%. Each additional day of delay beyond day 7 increases the odds of developing a coronary abnormality. However, treatment should not be withheld solely because fever has persisted beyond 10 days if there is evidence of ongoing inflammation or if the diagnosis remains clinically suspected. In these late-presenting cases, IVIG and aspirin still confer benefit, albeit with a smaller relative risk reduction.

Children who present with coronary artery dilatation or aneurysms at diagnosis require more intensive therapy and monitoring. Those with giant aneurysms (Z-score >10 or absolute diameter >8 mm) represent the highest-risk group and may require anticoagulation with warfarin or low-molecular-weight heparin in addition to aspirin. Such patients should be followed in specialized pediatric cardiology centers with expertise in Kawasaki disease.

Complications and Long-Term Management

The most feared complication of Kawasaki disease is coronary artery involvement. Aneurysms may regress over time, particularly small saccular aneurysms (Z-score <5). Up to 50% of small aneurysms undergo regression within the first 1–2 years. In contrast, giant aneurysms rarely regress and are associated with a high risk of thrombosis, stenosis, and myocardial infarction. These children require lifelong cardiology follow-up and often need interventional procedures such as catheter-based interventions, coronary artery bypass grafting, or, in severe cases, heart transplantation.

Beyond coronary aneurysms, Kawasaki disease can affect the heart in other ways. Myocarditis with reduced ventricular function is common during the acute phase but usually resolves with treatment. Valvular regurgitation, particularly mitral regurgitation, occurs in a subset of patients and may persist long-term. There is growing evidence that even children whose coronary arteries appear normal on echocardiography may have subclinical endothelial dysfunction and an increased risk of premature atherosclerosis later in life. This has important implications for long-term cardiovascular risk management.

The American Heart Association recommends lifelong follow-up for all patients with a history of Kawasaki disease. The frequency and intensity of follow-up depend on the severity of initial cardiac involvement:

  • Low risk: No coronary abnormalities at any stage – repeat echocardiography at 1 year, then every 3–5 years. Standard cardiovascular risk counseling.
  • Medium risk: Transient coronary dilatation that resolved – annual cardiology evaluation with echocardiography every 1–2 years. Periodic assessment of cardiovascular risk factors.
  • High risk: Persistent small to medium aneurysms – annual cardiology visits, echocardiography, and stress testing as the child grows. Low-dose aspirin indefinitely.
  • Very high risk: Giant aneurysms or obstructive lesions – more frequent monitoring, possibly anticoagulation, and consideration of invasive imaging. These patients require a multidisciplinary approach involving pediatric cardiology, interventional cardiology, and cardiac surgery.

Cardiovascular risk counseling should begin in childhood and emphasize heart-healthy lifestyle habits: a diet low in saturated fats and sodium, regular physical activity, avoidance of smoking and environmental tobacco exposure, and management of blood pressure and lipid levels. For children with coronary abnormalities, more aggressive risk factor modification is warranted, including pharmacotherapy for hypertension or dyslipidemia when indicated.

Prognosis and Future Directions

With current treatment protocols, the overall prognosis for children with Kawasaki disease is excellent. More than 95% of treated children recover without permanent cardiac damage. The mortality rate in developed nations is less than 0.1%, and most deaths occur in children with giant aneurysms who experience acute myocardial infarction. For children without coronary involvement, life expectancy and quality of life are comparable to the general population.

Ongoing research aims to identify the causative trigger, develop more targeted therapies, and improve risk stratification. Genetic studies have identified polymorphisms in ITPKC, CASP3, and FCGR2A that confer increased susceptibility and IVIG resistance, opening the door to personalized medicine approaches. Novel immunomodulatory agents, including interleukin-1 receptor antagonists such as anakinra, are being investigated for refractory cases. Additionally, the development of rapid diagnostic tests, possibly based on biomarkers or gene expression signatures, could help clinicians diagnose Kawasaki disease earlier and more accurately.

The emergence of MIS-C has renewed interest in Kawasaki disease pathogenesis and treatment. While distinct entities, the two conditions share overlapping clinical features and inflammatory pathways, suggesting that lessons learned from Kawasaki disease may inform the management of MIS-C, and vice versa. This convergence of research is accelerating progress in understanding post-infectious inflammatory syndromes in children.

Conclusion: Awareness Saves Hearts

Kawasaki disease remains a clinical diagnosis that depends on early recognition of fever together with a characteristic constellation of signs. Parents and caregivers should be taught to seek medical attention when a child has a high fever lasting more than five days, especially if accompanied by red eyes, a rash, swollen hands or feet, or changes in the lips and mouth. Healthcare providers must maintain a low threshold for considering Kawasaki disease in any infant or young child with unexplained prolonged fever, even when the classic clinical features are incomplete.

Early administration of IVIG and aspirin dramatically reduces the risk of coronary artery aneurysms and their long-term consequences. Once treated, lifelong surveillance is necessary for children with documented cardiac involvement, but the majority can expect a full recovery and a normal life expectancy. Increased public and professional awareness, combined with ongoing research to uncover the disease mechanism, offers the best path toward further reducing the burden of this potentially devastating childhood illness.

For additional information, the Centers for Disease Control and Prevention and the American Heart Association provide comprehensive resources for families and clinicians. The Mayo Clinic also offers an accessible overview of the condition.